主要文件

查看所有文档

S0441

SB-366791

Name: SB-366791
Brand: SIGMA

≥98% (HPLC), powder

别名:

N-(3-Methoxyphenyl)-4-chlorocinnamide

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₆H₁₄NO₂Cl

化学文摘社编号:

472981-92-3

分子量:

287.74

NACRES:

NA.77

PubChem Substance ID:

24278690

UNSPSC Code:

12352200

MDL number:

MFCD01033818

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

200

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

Quality Level

200

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear

originator

GlaxoSmithKline

SMILES string

COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1

InChI

1S/C16H14ClNO2/c1-20-15-4-2-3-14(11-15)18-16(19)10-7-12-5-8-13(17)9-6-12/h2-11H,1H3,(H,18,19)/b10-7+

InChI key

RYAMDQKWNKKFHD-JXMROGBWSA-N

Gene Information

human ... TRPV1(7442)

说明

Application

SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:

to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)
to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity
to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)

Biochem/physiol Actions

SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.

Vanilloid receptor-1 (TRPV1) antagonist.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

BGBC2715

091M4613V

022K4613

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Tibial post fracture pain is reduced in kinin receptors deficient mice and blunted by kinin receptor antagonists.

Vincent Minville et al.

Journal of translational medicine, 17(1), 346-346 (2019-10-24)

Tibial fracture is associated with inflammatory reaction leading to severe pain syndrome. Bradykinin receptor activation is involved in inflammatory reactions, but has never been investigated in fracture pain. This study aims at defining the role of B1 and B2-kinin receptors

SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain

Niiyama Y, et al.

British Journal of Anaesthesia, 102(2), 251-258 (2009)

AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.

Narender R Gavva et al.

The Journal of pharmacology and experimental therapeutics, 313(1), 474-484 (2004-12-24)

The vanilloid receptor 1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel expressed by peripheral sensory neurons. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Here, we describe the in vitro and in vivo

查看所有相关文献

全球贸易项目编号

货号	GTIN
S0441-25MG	04061832559544
S0441-5MG	04061832559551